PERSPECTIVE

SPRED proteins provide a NF-ty link to Ras suppression

Andrea I. McClatchey^{1,5} and Karen Cichowski^{2,3,4,5}

¹Massachusetts General Hospital Center for Cancer Research, Department of Pathology, Harvard Medical School, Charlestown, Massachusetts 02129, USA; ²Genetics Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, 02115, USA; ³Harvard Medical School, Boston, Massachusetts, 02115, USA; ⁴Ludwig Center at Dana-Farber, Harvard Cancer Center, Boston, Massachusetts 02115, USA

Mutations in the *SPRED1* (Sprouty-related protein with an EVH [Ena/Vasp homology] domain 1) and *NF1* (neurofibromatosis 1) genes underlie clinically related human disorders. The *NF1*-encoded protein neurofibromin is a Ras GTPase-activating protein (GAP) and can directly limit Ras activity. Spred proteins also negatively regulate Ras signaling, but the mechanism by which they do so is not clear. In the July 1, 2012, issue of *Genes & Development*, Stowe and colleagues (pp. 1421–1426) present evidence that *Spred1* recruits neurofibromin to the membrane, where it dampens growth factor-induced Ras activity, providing a satisfying explanation for the overlapping features of two human diseases.

The Ras pathway is critical for transducing extracellular signals to the nucleus and plays an essential role in a wide variety of biological processes. It has long been appreciated that the duration, amplitude, and subcellular localization of Ras activity must be tightly regulated to ensure physiologically appropriate responses (Marshall 1995). As such, cells use a slew of specialized negative feedback inhibitory proteins to control the intensity and duration of signaling triggered by exogenous stimuli (Kim and Bar-Sagi 2004; Chandarlapaty 2012). One family of negative regulators are the Sprouty and related Spred (Sprouty-related protein with an EVH [Ena/Vasp homology] domain) proteins, which have been shown to appropriately terminate Ras signaling following receptor tyrosine kinase (RTK) activation in vertebrates and invertebrates (Kim and Bar-Sagi 2004). However, over the years, it has become clear that these proteins function at several distinct levels within the Ras pathway. Moreover, the mechanisms by which these proteins function may be very context-specific, impinging on different components of the Ras/ERK pathway in response to different growth factors and in different tissues. The

complex and, in some instances, redundant mechanisms by which this protein family functions highlight the exquisite control that negative feedback pathways exert on intracellular signaling pathways and further suggest that this complexity has been biologically mandated.

The history of Sprouty and Spred proteins

Sprouty and Spred proteins share a conserved cysteine-rich C-terminal domain that has been dubbed the Sprouty (SPR) domain; beyond that, their domain architectures are distinct (Fig. 1). The first *Sprouty* gene was identified as a negative regulator of tracheal branching and FGF signaling in *Drosophila melanogaster* (Hacohen et al. 1998). There are four mouse and human *SPRY* family members (*SPRY1–4*) (Kim and Bar-Sagi 2004). In addition to the SPR domain, Sprouty proteins also share a region that contains a conserved tyrosine residue that has been shown to mediate interactions with Src homology-2 (SH2) domains (Fig. 1). Sprouty proteins have been shown to attenuate Ras/ERK signaling in response to several growth factors, including EGF, FGF, VEGF, PDGF, HGF, and SCF, among others (Cabrita and Christofori 2008). As such, *SPRY* gene expression is induced by the growth factors they regulate, as would be expected of proteins involved in negative feedback signaling (Kim and Bar-Sagi 2004). However their precise mechanism of action has been debated considerably.

Epistasis studies in *D. melanogaster* placed Sprouty upstream of Ras in response to EGF signaling in some tissues and at (or downstream from) Raf in others (Kim and Bar-Sagi 2004). In mammalian cells, Sprouty proteins have similarly been shown to function by suppressing either Ras or Raf activation, depending on the cell type. Notably, Sprouty proteins have been shown to interact with and sequester GRB2 (through the conserved phosphotyrosine) (Hanafusa et al. 2002) and bind and attenuate Raf activation (through the SPR domain) (Sasaki et al. 2003), and *D. melanogaster* Sprouty has been shown to bind and recruit Gap1, a Ras GTPase-activating protein (GAP) (Casci et al. 1999). These findings suggest that Sprouty proteins may function via different and/or redundant mechanisms, depending on cellular context, but, in all cases, play a critical role in suppressing Ras/ERK signaling. The SPR

[Keywords: Legius syndrome; NF1; signal transduction; Ras/MAPK; Sprouty]

⁵Corresponding authors

E-mail mcclatch@helix.mgh.harvard.edu

E-mail kcichowski@rics.bwh.harvard.edu

Article is online at <http://www.genesdev.org/cgi/doi/10.1101/gad.197434.112>.

Figure 1. Domain architecture of Sprouty and Spred proteins. (A) Sprouty and Spred proteins share a cysteine-rich C-terminal Sprouty (SPR) domain that is thought to mediate membrane localization and perhaps dimerization. Sprouty proteins also harbor a conserved tyrosine-containing motif (Y) that, when phosphorylated, can mediate GRB2 interaction. The Spred proteins, on the other hand, contain an N-terminal EVH1 domain and an intervening KBD whose functions are not well understood. (B) There are three Spred family members that share this domain architecture. Spred1 and Spred2 are most similar, particularly within the EVH1 and SPR domains. The KBD of Spred3 is poorly conserved and lacks key residues that are known to be important for c-Kit binding. Shown are the amino acid identities for the individual domains based on the human protein sequences.

domain appears to mediate membrane localization in part by directly binding phosphatidylinositol-(4,5)bisphosphate, although Sprouty proteins have been proposed to reside in several subcellular compartments (Kim and Bar-Sagi 2004). The SPR domain has also been reported to regulate dimerization (Cabrita and Christofori 2008).

The Sprouty-related Spred proteins possess a SPR domain but do not possess the conserved tyrosine residue present in Sproutys and therefore do not bind to GRB2 (Bundschu et al. 2007). However, in addition to the SPRY domain, Spred proteins also possess an N-terminal EVH1 domain and a central c-Kit-binding domain (KBD), hence the name Spred (Sprouty-related protein with an EVH domain). Spred1 and Spred2 were identified in a yeast two-hybrid screen designed to identify proteins that interact with the c-Kit kinase (Wakioka et al. 2001). The only other Spred, Spred3, exhibits similarity to Spred1 and Spred2 but does not possess a functional KBD. Like Sprouty proteins, Spred proteins inhibit ERK signaling in response to a number of growth factors, cytokines, and chemokines (Bundschu et al. 2007). Spred proteins have also been shown to interact in a complex with Ras (Wakioka et al. 2001); however, the precise function of Spred proteins has remained even more elusive than that of the Sproutys.

Mutations in *SPRED1* underlie a syndrome that is related to neurofibromatosis 1 (NF1)

An interesting clue to Spred function was revealed in 2007, when mutations in the *SPRED1* gene were identified in a subset of patients that were affected by what was thought to be a mild form of NF1 (Brems et al. 2007). NF1 is genetic disorder affecting one in 3500 individuals worldwide (Riccardi 1992). The disease features the dominant predisposition to a variety of clinical features, including

multiple café-au-lait spots, axillary freckling, macrocephaly, learning disorders, and bone defects, as well as numerous benign and malignant nervous system tumors. Loss-of-function mutations in *NF1* have also been detected in other sporadic cancers, including glioblastoma, neuroblastoma, and lung cancer (The Cancer Genome Atlas Research Network 2008; Parsons et al. 2008; McGillicuddy et al. 2009; Holzel et al. 2010). In the study published by Legius and colleagues (Brems et al. 2007), a variety of *SPRED1* mutations were found in a subset of patients that exhibited café-au-lait spots, axillary freckling, macrocephaly, and, in some instances, Noonan-like dysmorphic features; however, these patients did not develop tumors. The investigators further confirmed that these mutations resulted in a loss of function and that the cognate proteins were defective in their ability to suppress ERK signaling. Notably, this was the first report describing mutations in the *SPRY/SPRED* gene family in human disease. Patients that exhibit these symptoms are now routinely screened for *SPRED1* mutations, and this disorder has been dubbed “Legius syndrome” (Spurlock et al. 2009).

A mechanistic connection to the NF1 tumor suppressor protein

While the Spred proteins had been shown to be negative regulators of ERK signaling, and the overlapping phenotype with NF1 had been reported, the molecular mechanism by which Spred proteins function was still not known. In the July 1, 2012, issue of *Genes & Development*, Stowe et al. (2012) have now uncovered an interesting direct mechanistic connection between Spred1 and the *NF1*-encoded protein neurofibromin.

Neurofibromin is a RasGAP that negatively regulates Ras by catalyzing the hydrolysis of Ras-GTP to GDP (Bollag and McCormick 1992). Many studies have concluded that the pathogenesis conferred by *NF1* mutations is primarily due to hyperactive Ras (Cichowski and Jacks 2001). However, the contexts in which neurofibromin normally dampens Ras activity are still not entirely clear. A variety of growth factors have been shown to promote the proteasomal degradation of neurofibromin, and its degradation and subsequent re-expression are required for both the appropriate activation and termination of Ras signaling, respectively (Cichowski et al. 2003). However it should be noted that not all growth factors trigger neurofibromin degradation, and in some cell types, degradation is suppressed. Moreover, neurofibromin contains a small RasGAP domain (the GAP-related domain [GRD]) embedded within an otherwise very large protein. It is currently unclear how other regions of neurofibromin may couple it to specific growth factor receptors and/or regulate its function in specific subcellular locations.

Stowe et al. (2012) initially set out to understand how Spred1 negatively regulates Ras signaling. To do this, they first evaluated its effects on Ras-GTP levels directly and found that exogenous Spred1 can suppress EGF-induced Ras activation, supporting the notion, which had been debated, that Spred1 functions upstream of Ras, at least in this setting (Bundschu et al. 2007). Conversely, knockdown

of Spred1 resulted in an increase in Ras-GTP levels upon EGF stimulation. The investigators then carried out a careful series of structure–function studies using patient-derived missense *SPRED1* mutations. They found that mutations impacting the C-terminal SPR domain impaired the localization of Spred1 to the membrane, as might be expected from previous work (King et al. 2005). Interestingly, however, they found that the N-terminal mutations affecting the EVH1 domain still impaired the ability of Spred1 to dampen Ras-GTP levels. Artificial membrane targeting of C-terminal mutants rescued the function of SPR domain mutants, which was reversed by introducing EVH1 domain mutations. These results suggested that the EVH1 domain might mediate a protein–protein interaction that is critical for its suppressive effects on Ras.

With this hypothesis in mind, the investigators turned to an unbiased approach to identify such interacting partners. Using tandem affinity purification and mass spectrometry to identify proteins that specifically interact with a membrane-localized version of the Spred1 EVH1 domain (EVH1-CAAX), they identified neurofibromin.

By expressing ectopic Spred proteins, the investigators showed that neurofibromin coimmunoprecipitated with Spred1, Spred2, or Spred3 in a manner that was dependent on the N-terminal EVH1 domain. They were also able to capture the interaction between endogenous Spred1 and neurofibromin in mouse brain tissue. Moreover, they found that neurofibromin expression was necessary for Spred1-mediated inhibition of Ras-GTP and ERK levels in HEK-293 cells and mouse embryonic fibroblasts. Using both immunofluorescent localization and biochemical fractionation methods, they then showed that Spred1 actively recruits neurofibromin to the membrane. Again, patient mutations in the EVH domain of Spred1 disrupted its ability to relocate neurofibromin. Interestingly, the Spred1/neurofibromin interaction may represent a paradigm that is reminiscent of the Sprouty/Gap1 interaction in flies (Casci et al. 1999). A model of the proposed function of Spred1 and neurofibromin are shown in Figure 2.

This study not only reveals important mechanistic insight into Spred function, but also identifies a novel connection between Spred and neurofibromin, providing a satisfying explanation for the subset of overlapping phenotypes between NF1 and Legius syndrome patients. It also raises many interesting questions that can be explored in the years to come.

Future questions

While the EVH1 domain of Spred1 has been shown to mediate the interaction with neurofibromin, it will be interesting to identify the region of neurofibromin that interacts with Spred1, as the function of regions outside of the GRD is largely unknown. Interestingly, mutations in exon 17 of the *NF1* gene have been reported in families that exhibit a subset of clinical features that are similar to Legius syndrome, raising the intriguing possibility that there may be a domain in this region of neurofibromin that mediates the Spred1 interaction (Upadhyaya et al. 2007). Moreover, in what contexts is Spred1 used to

Figure 2. Model of Spred/NF1 functional interaction based on the recent work of Stowe et al. (2012). Their work suggests that Spred1 recruits neurofibromin to the membrane via its EVH1 domain. From this location, neurofibromin dampens the activity of membrane-localized, GTP-loaded Ras via its GRD. It should be noted that it is not yet clear whether Spred1 and neurofibromin interact directly or via an intermediary protein. Moreover, a key unanswered question concerns the nature of the signals that regulate the Spred:neurofibromin interaction. For example, it is not yet clear whether this is fundamentally a mechanism of negative feedback or a way to fine-tune signaling via cross-talk from other receptors.

recruit neurofibromin and dampen Ras activity? Do Spred proteins interact with neurofibromin downstream from certain receptors and/or in certain cell types? Neurofibromin does contain a PH-like/Sec14 domain, which has been proposed to regulate its membrane localization (D'Angelo et al. 2006); however, Spred proteins may bring neurofibromin to a specific signaling complex.

It will be important to look at the Spred/neurofibromin interaction in melanocytes, which underlie the café-au-lait spots and ancillary freckles that are features of NF1 and Legius syndrome. Interestingly, Spred1 and Spred2 were originally identified as c-Kit-interacting proteins (Wakioka et al. 2001). The role of the KBD in Spred function is not well understood, but it diverges among Spred family members; Spred3 lacks a key residue that is critical for the c-Kit interaction (Bundschiu et al. 2007). Notably, c-Kit plays a central role in melanocyte biology. Moreover, it is well known that c-Kit and neurofibromin function in a linear pathway in mast cells (Zhang et al. 1998). Hypomorphic mutations in c-Kit can even be rescued by heterozygous *Nf1* mutation in mice (Ingram et al. 2000). Although not discussed in the study, it is tempting to speculate that Spred1 and/or Spred2 may play a particularly important role in dampening c-Kit-mediated Ras activation through its interaction with neurofibromin. This might explain why the cutaneous and plexiform neurofibromas that commonly develop in NF1 patients are not a feature of Legius syndrome, as the cells of origin of those lesions are precursor Schwann cells that express little or no c-Kit (Zhu et al. 2002). Interestingly, Brems

et al. (2007) originally reported that café-au-lait spots show inactivation of the remaining *SPRED1* allele, suggesting that a complete loss of function is likely driving this phenotype. A similar loss of *NF1* has been observed in café-au-lait spots from NF1 patients (Maertens et al. 2007).

NF1 was identified >20 years ago. Although a number of interacting proteins have been reported, the significance of these interactions remains unclear (Bollag et al. 1993; Hsueh et al. 2001; De Schepper et al. 2006). It should be noted that neurofibromin binds the effector domain of Ras in a GTP-dependent manner (Bollag and McCormick 1992). However once neurofibromin binds Ras, GTP becomes hydrolyzed, presumably resulting in a dissociation from Ras and possibly the membrane. Neurofibromin is also initially destabilized by growth factors via the proteasome. It is likely that these features, in part, make neurofibromin–protein interactions very labile and difficult to detect, as they probably occur within a restricted time window following growth factor activation. Consistent with this possibility, Stowe et al. (2012) were able to capture an interaction between endogenous proteins most convincingly in postnatal brain lysates, where expression of both proteins is enriched and where one can generate very concentrated protein extracts. Moreover, the original interaction between the Spred EVH1-CAAX fragment and neurofibromin was detected in HEK-293 cells, one cell type in which neurofibromin is not degraded by growth factors (K Cichowski, unpubl.). Therefore the use of this cell type may have been fortuitous, in that neurofibromin may persistently attenuate EGFR signaling in these cells—at least in part by virtue of its constitutive stabilization. The outstanding questions, then, are as follows: How is the Spred/neurofibromin interaction normally regulated? How does this complex function in response to growth factors? Again, do specific receptors couple to this complex, and do different receptors use distinct Spred isoforms? The studies described by Stowe et al. (2012) provide an important launching point for future investigation.

A role for Spred proteins in cancer?

Finally, it is becoming increasingly apparent that neurofibromin plays a broader role in human cancer than once thought. Much less is known about Spred proteins. Reduced *Spred1* and *Spred2* expression has been proposed to underlie the progression of hepatocellular carcinoma in humans and osteosarcoma in mice (Miyoshi et al. 2004; Yoshida et al. 2006). Spred has also been shown to suppress tumor development and metastasis in various model systems (Yoshida et al. 2006). However, at this point, it is unclear how Spred might be lost or suppressed in human cancer. Nevertheless, if it is suppressed or mutated, might it be mediating its effects by compromising neurofibromin function? To this end, it should be noted that while *NF1*/neurofibromin is frequently mutated or suppressed in specific sporadic tumors, biallelic mutations and/or complete suppression is much less common (McGillicuddy et al. 2009). Might the suppression of *SPRED* or *SPROUTY* genes enhance the effects of

monoallelic mutations in *NF1*? These and other studies aimed at dissecting the complex mechanisms by which negative feedback pathways function continue to highlight the importance of these pathways in biology and human disease.

Acknowledgments

We thank members of the Cichowski and McClatchey laboratories for thoughtful discussions.

References

- Bollag G, McCormick F. 1992. Ras regulation. NF is enough of GAP. *Nature* **356**: 663–664.
- Bollag G, McCormick F, Clark R. 1993. Characterization of full-length neurofibromin: Tubulin inhibits Ras GAP activity. *EMBO J* **12**: 1923–1927.
- Brems H, Chmara M, Sahbatou M, Denayer E, Taniguchi K, Kato R, Somers R, Messiaen L, De Schepper S, Fryns JP, et al. 2007. Germline loss-of-function mutations in *SPRED1* cause a neurofibromatosis 1-like phenotype. *Nat Genet* **39**: 1120–1126.
- Bundschuh K, Walter U, Schuh K. 2007. Getting a first clue about SPRED functions. *Bioessays* **29**: 897–907.
- Cabrera MA, Christofori G. 2008. Sprouty proteins, masterminds of receptor tyrosine kinase signaling. *Angiogenesis* **11**: 53–62.
- The Cancer Genome Atlas Research Network. 2008. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature* **455**: 1061–1068.
- Casci T, Vinos J, Freeman M. 1999. Sprouty, an intracellular inhibitor of Ras signaling. *Cell* **96**: 655–665.
- Chandralapathy S. 2012. Negative feedback and adaptive resistance to the targeted therapy of cancer. *Cancer Discov* **2**: 311–319.
- Cichowski K, Jacks T. 2001. NF1 tumor suppressor gene function: Narrowing the GAP. *Cell* **104**: 593–604.
- Cichowski K, Santiago S, Jardim M, Johnson BW, Jacks T. 2003. Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor. *Genes Dev* **17**: 449–454.
- D'Angelo I, Welti S, Bonneau F, Scheffzek K. 2006. A novel bipartite phospholipid-binding module in the neurofibromatosis type 1 protein. *EMBO Rep* **7**: 174–179.
- De Schepper S, Boucneau JM, Westbroek W, Mommaas M, Onderwater J, Messiaen L, Naeyaert JM, Lambert JL. 2006. Neurofibromatosis type 1 protein and amyloid precursor protein interact in normal human melanocytes and colocalize with melanosomes. *J Invest Dermatol* **126**: 653–659.
- Hacohen N, Kramer S, Sutherland D, Hiromi Y, Krasnow MA. 1998. sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the *Drosophila* airways. *Cell* **92**: 253–263.
- Hanafusa H, Torii S, Yasunaga T, Nishida E. 2002. Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway. *Nat Cell Biol* **4**: 850–858.
- Holzel M, Huang S, Koster J, Ora I, Lakeman A, Caron H, Nijkamp W, Xie J, Callens T, Asgharzadeh S, et al. 2010. NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. *Cell* **142**: 218–229.
- Hsueh YP, Roberts AM, Volta M, Sheng M, Roberts RG. 2001. Bipartite interaction between neurofibromatosis type I protein (neurofibromin) and syndecan transmembrane heparan sulfate proteoglycans. *J Neurosci* **21**: 3764–3770.
- Ingram DA, Yang FC, Travers JB, Wenning MJ, Hiatt K, New S, Hood A, Shannon K, Williams DA, Clapp DW. 2000. Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo. *J Exp Med* **191**: 181–188.

- Kim HJ, Bar-Sagi D. 2004. Modulation of signalling by Sprouty: A developing story. *Nat Rev Mol Cell Biol* **5**: 441–450.
- King JA, Straffon AF, D'Abaco GM, Poon CL, I ST, Smith CM, Buchert M, Corcoran NM, Hall NE, Callus BA, et al. 2005. Distinct requirements for the Sprouty domain for functional activity of Spred proteins. *Biochem J* **388**: 445–454.
- Maertens O, De Schepper S, Vandesompele J, Brems H, Heyns I, Janssens S, Speleman F, Legius E, Messiaen L. 2007. Molecular dissection of isolated disease features in mosaic neurofibromatosis type 1. *Am J Hum Genet* **81**: 243–251.
- Marshall CJ. 1995. Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation. *Cell* **80**: 179–185.
- McGillcuddy LT, Fromm JA, Hollstein PE, Kubek S, Beroukhir R, De Raedt T, Johnson BW, Williams SM, Nghiemphu P, Liao LM, et al. 2009. Proteasomal and genetic inactivation of the Nf1 tumor suppressor in gliomagenesis. *Cancer Cell* **16**: 44–54.
- Miyoshi K, Wakioka T, Nishinakamura H, Kamio M, Yang L, Inoue M, Hasegawa M, Yonemitsu Y, Komiya S, Yoshimura A. 2004. The Sprouty-related protein, Spred, inhibits cell motility, metastasis, and Rho-mediated actin reorganization. *Oncogene* **23**: 5567–5576.
- Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et al. 2008. An integrated genomic analysis of human glioblastoma multiforme. *Science* **321**: 1807–1812.
- Riccardi VM. 1992. *Neurofibromatosis: Phenotype, natural history, and pathogenesis*. Johns Hopkins University Press, Baltimore.
- Sasaki A, Taketomi T, Kato R, Saeki K, Nonami A, Sasaki M, Kuriyama M, Saito N, Shibuya M, Yoshimura A. 2003. Mammalian Sprouty4 suppresses Ras-independent ERK activation by binding to Raf1. *Nat Cell Biol* **5**: 427–432.
- Spurlock G, Bennett E, Chuzhanova N, Thomas N, Jim HP, Side L, Davies S, Haan E, Kerr B, Huson SM, et al. 2009. SPRED1 mutations (Legius syndrome): Another clinically useful genotype for dissecting the neurofibromatosis type 1 phenotype. *J Med Genet* **46**: 431–437.
- Stowe IB, Mercado EL, Stowe TR, Bell EL, Oses-Prieto JA, Hernández H, Burlingame AL, McCormick F. 2012. A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1. *Genes Dev* **26**: 1421–1426.
- Upadhyaya M, Huson SM, Davies M, Thomas N, Chuzhanova N, Giovannini S, Evans DG, Howard E, Kerr B, Griffiths S, et al. 2007. An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the Nf1 gene (c.2970–2972 delAAT): Evidence of a clinically significant Nf1 genotype-phenotype correlation. *Am J Hum Genet* **80**: 140–151.
- Wakioka T, Sasaki A, Kato R, Shouda T, Matsumoto A, Miyoshi K, Tsuneoka M, Komiya S, Baron R, Yoshimura A. 2001. Spred is a Sprouty-related suppressor of Ras signalling. *Nature* **412**: 647–651.
- Yoshida T, Hisamoto T, Akiba J, Koga H, Nakamura K, Tokunaga Y, Hanada S, Kumemura H, Maeyama M, Harada M, et al. 2006. Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors. *Oncogene* **25**: 6056–6066.
- Zhang YY, Vik TA, Ryder JW, Srour EF, Jacks T, Shannon K, Clapp DW. 1998. Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines. *J Exp Med* **187**: 1893–1902.
- Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF. 2002. Neurofibromas in Nf1: Schwann cell origin and role of tumor environment. *Science* **296**: 920–922.

SPRED proteins provide a NF-ty link to Ras suppression

Andrea I. McClatchey and Karen Cichowski

Genes Dev. 2012, **26**:

Access the most recent version at doi:[10.1101/gad.197434.112](https://doi.org/10.1101/gad.197434.112)

Related Content	A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1 Irma B. Stowe, Ellen L. Mercado, Timothy R. Stowe, et al. Genes Dev. July , 2012 26: 1421-1426
References	This article cites 32 articles, 9 of which can be accessed free at: http://genesdev.cshlp.org/content/26/14/1515.full.html#ref-list-1 Articles cited in: http://genesdev.cshlp.org/content/26/14/1515.full.html#related-urls
License	
Email Alerting Service	Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or click here .

Focused on your science.

USC
SCIENTIFIC
SIDE BY SCIENCE